SFJ, Pfizer in deal for NSCLC product

SFJ Pharmaceuticals Inc. (Pleasanton, Calif.) agreed to fund and conduct a Phase III trial of dacomitinib from Pfizer Inc. (NYSE:PFE) in exchange for potential milestones and royalties tied to sales of the product in first-line non-small cell lung cancer. The trial, slated to start next half, will evaluate dacomitinib as a first-line treatment for locally advanced or metastatic NSCLC in patients across Asia and Europe with EGFR activating mutations. Dacomitinib is an inhibitor of human EGFR1, EGFR2 and EGFR4. Pfizer will retain regulatory and commercial responsibilities. SFJ declined to provide details. Dacomitinib is already in Phase III testing for second-line NSCLC. ...